article thumbnail

The Psychiatric Pipeline in Review: Quarter 2, 2025

Psychiatric Times

MindMed initiated a phase 3 study of MM120 for major depressive disorder, with results expected in the second half of 2026. Cybin partnered with Osmind to advance psychiatry programs, focusing on CYB003 and CYB004 for major depressive and generalized anxiety disorders.

article thumbnail

Psychotherapy and Psychosomatics: End of an Era for Independent Journals? An Interview With Giovanni Fava

Mad in America

Third, his journal told of the corrupting influence of pharmaceutical money on the creation of psychiatric diagnoses and drug trials. Whitaker: There are those two funding sources, open access where people have to pay, or journals where they’re basically funded by pharmaceutical advertisements. Fava: Right, and the libraries.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Psychiatry: Medical Science of Mind or Moral Ideology?

Mad in America

Doing so would also include allowing them to bear the potential consequences of rejecting assistance, such as legal action and social disapproval, as well as the consequences of requesting assistance, such as the potential harms of pharmaceutical interventions.

article thumbnail

Heritability Explains Less About Mental Disorders Than You Think

Mad in America

Number of genes Explained variance (%) Anxiety disorders 200,000 6 0.5 Bipolar disorder 413,000 64 4.6 Depressive disorder 1,154,000 178 1.5-3.2 Regarding mental disorders, pharmaceutical treatments appear better if genetic causes are assumed. Malfunction Number of persons (approx.) ADHD 55,000 12 5.5

article thumbnail

Do Critics of Biological Psychiatry Have an Alternative to a Life of “Whack-A-Mole”?

Mad in America

This turn to ketamine is occurring despite the fact that the Food and Drug Administration has repeatedly warned that the FDA has not approved ketamine for the treatment of any psychiatric disorder (though controversially approving esketamine nasal spray). accepting personal or office gifts or corporate donations from industry.

article thumbnail

Psychology, Personhood, and the Crisis of Neoliberalism: Jeff Sugarman on Theoretical and Critical Psychology

Mad in America

In one of your articles on neoliberalism and psychological ethics, you discuss the striking increase in social anxiety diagnoses over the past 30 years. Then, as the DSM revised its classificationsreplacing multiple personality disorder with dissociative identity disorder the diagnosis largely disappeared.

article thumbnail

Branding Diseases—How Drug Companies Market Psychiatric Conditions: An Interview with Ray Moynihan

Mad in America

For the pharmaceutical industry, the bigger and wider those diseases, the more people who can be diagnosed, and the bigger your markets are. The marketing of medical conditions has become a key plank of pharmaceutical industry marketing. Helping widen the definitions of disease is a key part of marketing those pharmaceutical products.